Daniel Clark, an analyst at Leerink Partners, announced the first coverage of eye care product company Bausch & Johnson, giving it a “outperforming the market” rating and setting a target price of $24. Leerink Partners believes that the target price implies an increase of about 35.4% from Tuesday's closing price. Analysts pointed out that the core logic of optimism about the company's growth prospects is that it has growth potential in several key business areas, and believes that Bausch & Lohn has multiple potential growth entry points on core tracks such as dry eye treatment, contact lenses, and high-end intraocular lenses.

Daniel Clark, an analyst at Leerink Partners, announced the first coverage of eye care product company Bausch & Johnson, giving it a “outperforming the market” rating and setting a target price of $24. Leerink Partners believes that the target price implies an increase of about 35.4% from Tuesday's closing price. Analysts pointed out that the core logic of optimism about the company's growth prospects is that it has growth potential in several key business areas, and believes that Bausch & Lohn has multiple potential growth entry points on core tracks such as dry eye treatment, contact lenses, and high-end intraocular lenses.